The Future of Oncology is Personal, and It’s Already Here

A decade ago, the idea of designing a cancer treatment around an individual’s unique genetic profile was largely aspirational. Today, this is becoming a standard practice. The rise of precision oncology — fueled by immunotherapies, targeted biologics and CGTs — is ushering in a new era of possibility for patients and providers alike.

Yet, because these advanced innovations are so targeted, they’re also ushering an unprecedented level of complexity into the care journey. Navigating this complexity requires continuous innovation across science, logistics and patient support as therapies move through clinical development to approval and real-world practice.

At McKesson, we recognize that realizing the full promise of precision oncology requires more than scientific progress; it demands an ecosystem capable of supporting these therapies end-to-end that seamlessly connects biopharma manufacturers, providers, payers and patients.

Through our deep expertise in specialty logistics, specialty pharmacy and patient support, we’ve built the infrastructure to enable more patients to benefit from these transformative medicines. This is particularly important in community settings, where the majority of patients reside and where access to precision therapies is often more challenging.

McKesson touches many points in the precision medicine journey, from development to commercialization and distribution. Here are three ways we’re helping to ensure that these therapies reach the patients who need them.

Expanding Facilities to Support Cold-Chain Logistics

Many precision medicines must be stored and transported at temperatures well below zero, often under tight time constraints and with no room for error. That means every hand off in the supply chain must be tightly coordinated, monitored and controlled.

To meet this need, McKesson has invested in a state-of-the-art cold chain storage facility purpose-built for CGTs. Designed from the ground up by our experts at InspiroGene™ by McKesson, the facility supports the full temperature range — from ambient to cryogenic — within a single, integrated site.

It combines advanced storage, repackaging and prepared treatment kit capabilities with integrated specialty pharmacy and distribution services that deliver the speed, precision and reliability that CGTs demand.

Built for scalability, the facility is designed to evolve alongside the expanding CGT pipeline and ensure that therapies can reach patients without delay or compromise.

Tailoring Patient Support Through Specialty Pharmacy and Hub Services

While the science behind precision oncology is highly sophisticated, the patient experience must be as seamless and supportive as possible. For many patients, these therapies represent both a new treatment option and a complex new journey that involves genetic testing, multistep insurance authorizations and sometimes travel and coordination across multiple care settings.

This complexity demands an integrated services model, not a fragmented one. These patients are critically ill, and success depends on having dedicated case managers who can connect the dots between payers, providers and caregivers.

Through Biologics by McKesson, we deliver specialty pharmacy solutions tailored to the unique needs of patients receiving advanced therapies. Our teams provide education and counseling, benefits investigation, prior authorization assistance, infusion coordination and adherence support — all delivered with speed so we can help patients get on therapy quickly and manage their treatment effectively.

To further elevate the patient experience in cell and gene therapy, Biologics and InspiroGene recently partnered to launch InspiroCare, a dedicated, high-touch CGT hub that guides patients through every step of their treatment journey. From coordinating with providers to navigating insurance and logistics, InspiroCare offers personalized concierge support designed to reduce friction and remove potential access barriers for patients and caregivers alike.

Partnering with Community Oncology Practices to Support Adoption

Integrating biomarker-directed therapies into clinical workflows can raise challenges, from ordering and interpreting tests to navigating payer coverage and data reporting requirements.

Through Precision Care Companion (PCC), McKesson and The US Oncology Network are helping community practices overcome these barriers. PCC brings together a consortium of industry experts focused on accelerating precision medicine adoption across the community setting.

The program delivers targeted education, technology enhancements, operational best practices and detailed analytics on biomarker testing rates by cancer type to empower practices with the insights and tools they need to make precision care routine.

This model reflects our broader philosophy that advancing precision oncology is not just about developing new therapies but about ensuring every patient in every community can access the right drug at the right time.

Delivering the Promise of Precision Medicine

A new era of personalized medicine is transforming the future of cancer care. For McKesson, supporting that transformation means connecting every link in the patient journey, from when a therapy leaves the manufacturer’s facility through the moment it reaches a patient.

By integrating best-in-class logistics, specialty pharmacy, patient support and practice solutions, we’re helping build a system that’s as precise and adaptive as the therapies themselves. Together with our partners across the oncology ecosystem, we’re ensuring that precision medicine goes beyond scientific breakthrough to become a reliable and accessible standard of care that delivers on its full promise for patients everywhere.